“In studies involving 100 volunteers in Russia and 100 volunteers in Azerbaijan, the combination of drugs demonstrated an optimal safety and tolerability profile, which is consistent with the results of previous clinical studies,” RDIF said.
In January, it was reported that AstraZeneca would file documents for registration of its coronavirus vaccine in Russia after receiving the results of a study on the combined use of AstraZeneca and Sputnik Light coronavirus vaccines.
The RDIF noted that the combination of the Russian coronavirus vaccine Sputnik Light with other vaccines after 14 days gives a greater immune response than when using a single vaccine.
In November, the fund said that a study of the Sputnik V coronavirus vaccine in Belarus showed the effectiveness of the drug at the level of 96.3%.